Related Experiment Videos
The tumor microenvironment: focus on myeloma.
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. dalton@moffitt.usf.edu
Cancer Treatment Reviews
|May 10, 2003
Summary
Tumor cells develop drug resistance through various mechanisms, including cell adhesion to the extracellular matrix. This cell adhesion-mediated drug resistance (CAM-DR) is crucial in hematologic cancers like multiple myeloma.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Cancer cells exhibit diverse drug resistance mechanisms.
- These include efflux pumps, altered apoptosis factors, and enzyme activity.
- Cellular drug resistance is also influenced by interactions with the extracellular matrix (ECM).
Purpose of the Study:
- To explore the role of cell adhesion-mediated drug resistance (CAM-DR) in cancer.
- To investigate CAM-DR in hematologic malignancies, specifically multiple myeloma.
- To understand how the tumor microenvironment contributes to chemotherapy resistance.
Main Methods:
- Review of known cellular resistance mechanisms.
- Focus on the impact of extracellular matrix (ECM) protein binding.
- Analysis of CAM-DR relevance in multiple myeloma.
Main Results:
- Cell adhesion to ECM proteins is a significant factor in drug resistance.
- CAM-DR is particularly relevant in hematologic malignancies like multiple myeloma.
- Myeloma cell adhesion to bone marrow stroma promotes survival.
Conclusions:
- Cell adhesion-mediated drug resistance (CAM-DR) offers a protective mechanism for tumor cells.
- The tumor microenvironment plays a critical role in mediating chemotherapy resistance.
- Understanding CAM-DR is key to overcoming drug resistance in cancers such as multiple myeloma.